1
|
Azar ST, Echtay A, Amm M, Ballout H, Cheaib I, El Nazer H, Fardoun I, Ghazzawi A, Kenaan R, Merheb M, Obeid Y, Saleh M, Wakim S, Zein C. Characteristics and treatment patterns of patients with type 2 diabetes in Lebanon: the DISCOVER study. East Mediterr Health J 2021; 27:509-515. [PMID: 34080680 DOI: 10.26719/2021.27.5.509] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Accepted: 06/22/2020] [Indexed: 11/09/2022]
Abstract
Background Lebanon is part of the global DISCOVER study, a global, noninterventional, multicentre, prospective study with 3-years of follow-up. Aims The aim of this study is to describe real-world clinical practice in terms of type 2 diabetes mellitus (T2DM) disease management and treatment patterns within Lebanon. Methods Baseline demographic and clinical parameters were captured on a standardized case report form, according to routine clinical practice at each clinical site. Results We recruited 348 patients. At the initiation of second-line therapy, mean duration of diabetes was 6.7 [standard deviation (SD) 6.5] years; mean HbA1c and fasting plasma glucose levels were 8.5% (SD 1.6%) and 178.7 (SD 56.5) mg/dL respectively. Almost half the patients were hypertensive (45.1%) or had dyslipidaemia (48.6%). Metformin monotherapy was used as first-line therapy in 56.9% of the patients and upfront dual therapy in 25%. The primary reason for changing firstline therapy was poor glycaemic control. The main factors in choosing the second-line therapy were efficacy, tolerability and hypoglycaemia. Conclusion Clinical inertia was evident in this cohort of patients as they had suboptimal glycaemic control at the time of enrolment and the initiation of second-line therapy. Treatment intensification is required to reduce diabetes-related adverse outcomes.
Collapse
Affiliation(s)
- Sami T Azar
- Endocrinology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - Akram Echtay
- Endocrinology Division, Department of Medicine, Rafik Hariri University Hospital, Beirut, Lebanon
| | | | | | | | - Hicham El Nazer
- Endocrinology Division, Department of Medicine, Rafik Hariri University Hospital, Beirut, Lebanon
| | - Ihab Fardoun
- Endocrinology Division, Department of Medicine, Rafik Hariri University Hospital, Beirut, Lebanon
| | - Ahmad Ghazzawi
- Endocrinology Division, Department of Medicine, Rafik Hariri University Hospital, Beirut, Lebanon
| | - Rafic Kenaan
- Endocrinology Division, Department of Medicine, Hammoud Hospital University Medical Center, Beirut, Lebanon
| | - Marie Merheb
- Endocrinology Division, Department of Medicine, Mount Lebanon Hospital and Gharios Medical Center, Beirut, Lebanon
| | - Yousef Obeid
- Endocrinology Division, Department of Medicine, Rafik Hariri University Hospital, Beirut, Lebanon
| | - Mounzer Saleh
- Endocrinology Division, Department of Medicine, Rafik Hariri University Hospital, Beirut, Lebanon
| | - Saria Wakim
- Endocrinology Division, Department of Medicine, Saint Joseph Hospital, Beirut, Lebanon
| | - Camille Zein
- Endocrinology Division, Department of Medicine, Rafik Hariri University Hospital, Beirut, Lebanon
| | | |
Collapse
|